New antidiabetic therapy and HFpEF: light at the end of tunnel?

Marijana Tadic1, Carla Sala2, Sahrai Saeed3, Guido Grassi4, Giuseppe Mancia5, Wolfgang Rottbauer1, Cesare Cuspidi4,6

Accepted: 6 April 2021 / Published online: 11 April 2021
© The Author(s) 2021

Abstract
New antidiabetic therapy that includes sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors showed significant benefit on cardiovascular outcomes in patients with and without type 2 diabetes mellitus, and this was particularly confirmed for SGLT2 inhibitors in subjects with heart failure (HF) with reduced ejection fraction (HFrEF). Their role on patients with HF with preserved ejection fraction (HFpEF) is still not elucidated, but encouraging results coming from the clinical studies indicate their beneficial role. The role of GLP-1R agonists and particularly DPP-4 inhibitors is less clear and debatable. Findings from the meta-analyses are sending positive message about the use of GLP-1R agonists in HFrEF therapy and revealed the improvement of left ventricular (LV) diastolic function in HFpEF. Nevertheless, the relevant medical societies still consider their effect as neutral or insufficiently investigated in HF patients. The impact of DPP-4 inhibitors in HF is the most controversial due to conflicting data that range from negative impact and increased risk of hospitalization due to HF, throughout neutral effect, to beneficial influence on LV diastolic dysfunction. However, this is a very heterogeneous group of medications and some professional societies made clear discrepancy between saxagliptin that might increase risk of HF hospitalization and those DPP-4 inhibitors that have no effect on hospitalization. The aim of this review is to summarize current clinical evidence about the effect of new antidiabetic medications on LV diastolic function and their potential benefits in HFpEF patients.

Keywords
SGLT2 inhibitors · GLP-1 receptor agonists · DPP-4 inhibitors · Left ventricular · Diastolic function · Heart failure

Introduction
Heart failure with preserved ejection fraction (HFpEF) makes almost the half of all patients with heart failure (HF) [1]. The existing trend of increased HFpEF prevalence is the consequence of elevated incidence of hypertension, diabetes, and obesity, as well as normal aging of population [1]. Significant improvement in the cardiovascular imaging techniques and particularly echocardiography and magnetic resonance imaging has contributed to early detection and more precise evaluation of left ventricular (LV) diastolic dysfunction and increased number of diagnosed HFpEF patients.

There are no guidelines for specific treatment of HFpEF. The same medications used in the large therapeutic armamentarium in patients with heart failure with reduced ejection fraction (HFrEF) are used in HFpEF. Nevertheless, the significant improvement was made in the treatment of HFrEF in the last decade and some new medications with new mechanisms of actions were approved for clinical usage. One of the most important is the angiotensin receptor II blocker-neprilysin inhibitor (ARNI), sacubitril-valsartan that has significantly changed the practice in HFrEF treatment and became an established part of therapy in these patients.
However, the impact of sacubitril-valsartan in HFpEF is still not fully understood. Results from studies are still controversial, but latest data showed beneficial effect in some HFpEF patients with lower range of left ventricular ejection fraction (LVEF) and women [3], which is why the Federal Drug Agency recently approved sacubitril-valsartan in these patients [4].

More recently new antidiabetic medications showed significant improvement in patients with HFrEF regardless of the presence of DM [5–7], but data in HFpEF are still scarce until ongoing trials do not provide evidence [8]. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors showed significant benefit on cardiovascular outcomes in both patients with and without type 2 diabetes mellitus (DM) [2].

The aim of this review is to summarize current clinical knowledge about the effect of new antidiabetic medications on LV diastolic function and potential clinical benefits in HFpEF patients.

The effects of SGLT2 inhibitors on cardiovascular system

Preclinical and clinical studies showed significant positive pleotropic effects on kidneys, liver, pancreas, blood plasma, blood vessels, and adipose tissue that result with decreased preload and afterload, reduced fibrosis, oxygen demand, and LV hypertrophy, as well as decreased afterload [9]. The effect of SGLT2 inhibitors is achieved through SGLT2, a sodium-glucose co-transporter located on the apical membrane of the renal proximal convoluted tubules. It is responsible for more than 90% of glucose reabsorption in the kidney, whereas the rest is achieved by SGLT1 in the descending arm of the loop of Henle [9]. The difference in glucose concentration between cytoplasm and plasma enables the passive glucose transport through the basolateral membrane. The glycosuria resulting from SGLT2 inhibition is proportional to the level of blood glucose. SGLT2 inhibitors show a modest efficacy in lowering plasma glucose levels, reducing HbA1c by approximately 0.5–1%.

The diuretic and natriuretic effects of SGLT2 inhibitors induce depletion in plasma volume, which is the most important to prevent fluid retention and HF exacerbation. At difference from traditional diuretics, these medications have been shown to reduce not only intravascular volume but also interstitial fluid; this mechanism may exert adverse effects in HF patients with reduced intravascular volume and induce diuretic resistance.

The diuretic effect of SGLT2 inhibitors is associated with reduced preload and LV filling pressure, myocardial stretching, and myocardial interstitial fibrosis. Furthermore, the reduction in extracellular fluid volume is associated with decrease in blood pressure [10, 11], which is even more amplified with the reduction in body mass induced by SGLT2 inhibitors [11]. This weight loss is related with increased glucose excretion in the urine and loss of extracellular fluid. Böhme et al. reported that SGLT2 inhibitor (empagliflozin) reduced risk of heart failure, as well as cardiovascular and renal outcomes independently of mean systolic blood pressure during the trial [12]. These results suggest a BP-independent effect of empagliflozin on cardiovascular and heart failure outcomes.

Studies also showed that SGLT2 inhibitors reduced albuminuria, the urinary albumin to creatinine ratio, and slowed the progression from microalbuminuria to macroalbuminuria [13]. Investigations also reported improved endothelial function, reduced oxidative stress and inflammation, and decreased aortic stiffness in patients treated with SGLT2 inhibitors [14]. These mechanisms are associated with reduction in central blood pressure, pulse pressure, and forward wave amplitude [15], which can be helpful in patients with HF. Recent investigations revealed sympathetic nervous system reduction in patients treated with SGLT2 inhibitors [16], which might partly explain beneficial effect in patients with HF.

SGLT2 inhibitors and LV diastolic function

Studies that involved patients with DM showed significant improvement in LV diastolic function I patients treated with SGLT2 inhibitors [17–23] (Table 1). Meta-analysis that investigated effects of antidiabetic drug on LV function showed that SGLT-2 inhibitors were more significantly associated with improved LV end-diastolic diameter and E/e′ [17]. There was no significant difference in mean change in the treatment effect of e′ and E/A between any of the 6 drugs and placebo or in pairwise comparisons between any two of the 6 drugs (SGLT2 inhibitors, DPP4 inhibitors, GLP1 agonists, metformin, sulfonylurea, and thiazolidinediones [17]).

Empagliflozin given in subjects with DM and history of cardiovascular (CV) disease showed reduction in LV mass index and LV end-diastolic volume, as well as better parameters of LV diastolic function after 3 or 6 months of therapy [18, 19]. More recent data from the EMPA-REG OUTCOME trial revealed that empagliflozin treatment of patients with DM had no significant effect on hemodynamic parameters during 3 months of therapy, but it induced rapid and sustained improvement of LV diastolic function (E/e′) [20]. Therapy with SGLT2 inhibitors proscribed after acute myocardial infarction was not associated with better LVEF or LV longitudinal strain, but it was related with favorable changes in diastolic function parameters [21]. Other investigation reported only minor effect of empagliflozin on LV
diastolic function in DM patients with albuminuria and preserved LVEF [22]. However, the recent study showed that empagliflozin improved LV diastolic function only in patients HFrEF, but not in those with normal LVEF and without HF [23] (Table 1).

Recently published data from the IDDIA trial showed that dapagliflozin in addition to standard antihyperglycemic therapy in patients with type 2 DM was related with a significant improvement in LV diastolic dysfunction evaluated with diastolic stress echocardiography as compared with placebo [24]. The use of dapagliflozin resulted in a significant reduction of LV filling pressure evaluated by E/e′ during exercise in patients with type 2 DM.
Matsutani et al. reported that 3-month therapy with canagliflozin in DM patients (approximately 30% had CV disease) significantly reduced LV mass index and E/e′ [25]. Tofogliflozin was also proven to have positive effect on E/e′ in DM patients without CV disease who were treated with this agent for approximately 8 months [26] (Table 1).

**SGLT2 inhibitors and HFpEF**

Data regarding use of SGLT2 inhibitors in HFpEF are scarce and mostly based on studies with limited number of participants. From pathophysiological perspective, the prescription of these medications would be justifiable because of favorable effect on LV filling pressure reduction and LV diastolic function improvement, which are the key points in treatment of HFpEF. In the recently published network meta-analysis, SGLT-2 inhibitors showed the largest risk reduction for HF hospitalization compared with placebo [7]. Additionally, SGLT-2 inhibitors were related with significant risk reduction in pairwise comparisons with both GLP-1R agonists and DPP-4 inhibitors. Study demonstrated 99.6% probability of SGLT-2 inhibitors being the optimal treatment for reducing the risk of HF outcome, followed by GLP-1 agonists (0.27%) and DPP-4 inhibitors (0.1%) [7].

Small investigation reported that 6-month therapy with dapagliflozin significantly improved LV diastolic function (E/e′ and left atrial volume index) in HFpEF patients with DM, even though there was no significant change in BNP [26]. Re-evaluation of these data demonstrated significant improvement not only in LV diastolic function but also in LV longitudinal strain only in HFpEF patients but not in HFrEF subjects [28]. This improvement in LV longitudinal strain was independently of demographic, clinical, and echocardiographic parameters associated with E/e′ after administration of dapagliflozin [28].

Another small study that investigated the effect of canagliflozin on LV remodeling in DM patients with HF (majority of patients—33/35 had HFpEF) showed that LV filling pressure, assessed by E/e′, significantly decreased after 6 months of treatment and effect was sustained even after 12 months of therapy [29] (Table 2).

The STADIA-HFpEF trial will evaluate the direct effects of 13-week therapy with dapagliflozin on LV stiffness in

| Reference                        | Sample size | Medication       | Follow-up period | Main findings                                                                                                                                                                                                 |
|----------------------------------|-------------|------------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bizino et al. [32]               | 49 DM patients | Liraglutide     | 26 weeks        | Reduced early LV diastolic filling and LV filling pressure, as well as decreased LVEF, but it did not change cardiac output and cardiac index. LVEF remained within normal range                                            |
| Saponaro et al. [33]             | 37 DM patients | Liraglutide     | 6 months        | Significant improvement in LV diastolic function (E/A, E/e′)                                                                                                                                                    |
| Hiramatsu et al. [34]            | 139 DM patients | Liraglutide    | 48 months       | E/e′ and LA volume index significantly improved                                                                                                                                                    |
| Ida et al. [35]                  | 592 DM patients (meta-analysis) | Liraglutide | -               | Liraglutide caused a significant improvement in LV diastolic function in comparison with other anti diabetic drugs (sitagliptin, linagliptin, pioglitazone, rosiglitazone, voglibose, and glimepiride) |
| Lambadiari et al. [36]           | 60 DM patients | Liraglutide     | 6 months        | Improved arterial stiffness, LV myocardial strain, LV twisting and untwisting and NT-proBNP by reducing oxidative stress in patients with newly diagnosed DM, did not demonstrate significant improvement in LV diastolic function comparing with placebo |
| Kumarathurai et al. [37]         | 30 DM diabetes | Liraglutide    | 24 weeks        | Liraglutide therapy did not improve any diastolic function parameters in subjects with DM, CAD, and preserved LVEF                                                                               |
| Scalzo et al. [38]               | 23 DM patients | Exanatide       | 3 months        | Improved significantly LV diastolic function and reduced arterial stiffness after 3 months of therapy, but did not improve functional exercise capacity                              |
| Zhang et al. [17]                | 4790 DM patients (meta-analysis) | Liraglutide | -               | GLP-1 agonists are more significantly associated with improved LVEF, LVESV and E/e′                                                                                                                       |

**Table 2** GLP-1R agonists and left ventricular diastolic function

*CAD* coronary artery disease *DM* diabetes mellitus *GLP-1* glucagon-like peptide-1 receptor *LA* left atrial *LVEF* left ventricular ejection fraction *LVESV* left ventricular end-systolic volume
patients with HFrEF, and primary endpoint is echocardiographically derived change in E/e', LV end-diastolic volume index, and change in mean LV e' [30].

The largest ongoing trial on this topic is the EMPEROR-Pruned study that enrolled 5988 symptomatic HF patients LVEF > 40% with and without type 2 DM of which one-third have LVEF between 40 and 50% (HF with mid-range LVEF), and two-third with LVEF > 50% (HFrEF) [8]. The presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) was common, and the majority of the patients are treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients are on mineralocorticoid receptor antagonists [8]. The expected follow-up is 38 months. It is expected that this trial will provide many answers about the usefulness of SGLT2 inhibitors, particularly dapagliflozin, on outcome and LV remodeling in HFrEF and HFmrEF patients.

The effects of GLP-1 receptor (GLP-1R) agonists on cardiovascular system

Secretion of GLP-1 stimulates insulin release by pancreatic beta-cells in a glucose-dependent correlation and reduces glucagon secretion by alpha-cells. GLP-1 reduces postprandial glucose by slowing gastric emptying, reducing intestinal glucose uptake, suppressing hepatic glucose production, and improving insulin sensitivity of muscle and liver [31]. The main limitation of endogenous GLP-1 is extremely short half-life (approximately 2 min) due to the activation of enzyme dipeptidylpeptidase-4 (DPP-4). There are only two possibilities to overcome this problem: inhibition of DPP-4 to prevent early breakdown of GLP-1 and invention of GLP-1R agonists that are resistant to degradation by DPP-4 and simulate the effect of GLP-1 [31].

Cardiovascular effects of GLP-1R are reduced activity of renin–angiotensin–aldosterone system, reduced oxidative stress, decreased blood pressure, improved endothelial function and microvascular perfusion, and reduced triglycerides and LDL levels. The negative effect might be increased sympathetic nervous system activity and direct sinoatrial node stimulation, which consequently increases heart rate [31].

GLP-1R agonists and LV diastolic function

Growing body of evidence shows significant beneficial effect of GLP-1R agonists on LV diastolic function in patients with type 2 DM [32, 33]. Studies that investigated patients with type 2 DM and without cardiovascular disease revealed that liraglutide significantly increased e' and decreased E/e' and LV end-diastolic volume, which reflects reduction in LV filling pressure [32, 33] (Table 2). Hiramatsu et al. reported that liraglutide was effective for glucose and blood pressure reduction, reduced albuminuria, and improved LV diastolic function [34]. The authors showed that LV diastolic function was not improved by sitagliptin and linagliptin [34]. The meta-analysis that included 592 patients treated with different oral antidiabetic drugs (sitagliptin, linagliptin, pioglitazone, rosiglitazone, voglibose, and glimepiride) showed that only liraglutide was associated with significant improvement of LV diastolic function [35] (Table 2). Lambadiari et al. revealed that 6-month treatment with liraglutide improved arterial stiffness, LV myocardial strain, LV twisting, and untwisting by reducing oxidative stress in subjects with newly diagnosed DM [36].

Recent investigation that involved patients with DM and coronary artery disease with preserved LVEF treated with liraglutide did not demonstrate significant improvement in LV diastolic function comparing with placebo [37]. Administration of exanatide in patients with DM improved significantly LV diastolic function and reduced arterial stiffness after 3 months of therapy, but did not improve functional exercise capacity [38]. Zhang et al. in meta-analysis reported that GLP-1 agonists are significantly associated with improved LVEF, LV end-systolic volume, and E/e' [17] (Table 2).

GLP-1R agonists and heart failure

GLP-1R agonists were not investigated in patients with HFrEF so far. However, studies conducted in DM patients with stable HFrEF did not support the use of liraglutide in patients with HFrEF and raised the questions about the safety of liraglutide in these subjects [39, 40]. The FIGHT study did not find significant changes in LVEF, pro-BNP, HbA1c, heart rate, LV end-systolic volume index, LV end-diastolic volume index, and 6-min walking when DM patients with HFrEF were treated with liraglutide for 6 months in comparison with placebo control group [39]. There were no significant differences in mortality or rehospitalization rate due to heart failure between liraglutide and placebo group [39]. The LIVE study revealed that liraglutide significantly reduced HbA1c and increased 6-min walking test [40]. However, it increased elevated heart rate and number of serious cardiac adverse events in comparison with control group. There were no statistical differences in LVEF, pro-BNP, LV end-systolic volume index, and LV end-diastolic volume index [40]. These findings raised some concerns with respect to the use of liraglutide in patients with chronic HFrEF. Even though dedicated studies were not positive, the recent meta-analysis reported 9% reduction in hospitalization rate for HF in patients treated with GLP-1R agonists [41].

Animal model of HFpEF showed that a 4-week GLP-1R agonist treatment via osmotic pumps significantly improved survival (70%) and reduced LV stiffness, LV diastolic...
dysfunction, and pulmonary congestion [42]. Another animal study in HFpEF mouse model reported that treatment with liraglutide attenuated the cardiometabolic dysregulation and improved cardiac function, with reduced cardiac hypertrophy, less myocardial fibrosis, and reduction of atrial weight, natriuretic peptide levels, and lung congestion [43]. These findings are encouraging and warrant further investigation in humans with HFpEF.

**DPP-4 and cardiovascular system**

DPP-4 (dipeptidyl peptidase-4) inhibitors are responsible for the degradation of two gut-derived incretin hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). DPP-4 inhibitors progressively replaced sulfonylureas in therapy of type 2 DM in many countries because they are not related with hypoglycemia or weight gain and they have good safety profile and comfortable usage even in patients with chronic renal failure [44]. Even though DPP-4 inhibitors mainly use GLP-1 pathway, they do not show that high level of cardiovascular protection as GLP-1R antagonists [44]. The reasons probably lay in the fact that some other DPP-4 regulated substrates are also cardioactive, such as stromal cell-derived factor-1 and brain natriuretic peptide [45], which is why controversies exist about the role of DPP-4 inhibitors in deterioration of HF and increased number of hospitalizations in these patients [44]. The majority of studies showed only non-inferiority of DPP-4 inhibitors with the respect of major adverse cardiovascular events (stroke, nonfatal myocardial infarction, and cardiovascular death) [46–48]. These are data from major trials that investigated the effect of saxagliptin, alogliptin, sitagliptin and linagliptin [45–47]. However, significant concern was raised because some studies showed increased rate of hospitalization due to heart failure [46]. Nevertheless, study that investigated the effects of sitagliptin in DM patients did not find any increase of hospitalizations due to HF [49]. This only confirms the ongoing controversies about the efficacy of DPP-4 inhibitors in DM patients with CV diseases.

**DPP-4 inhibitors and LV diastolic function**

The limited data about the effect of DPP-4 inhibitors and LV diastolic function are inconsistent. Some studies showed the significant decrease in E/e′ ratio in poorly controlled DM patients treated with sitagliptin [50–52] (Table 3). Small study that included 25 DM patients treated with different DPP-4 inhibitors (19 on sitagliptin, 5 on vildagliptin and 1 on saxagliptin) reported significant improvement in LV longitudinal strain and E/e′, surrogates of LV systolic and diastolic functions, and important improvement in endothelial function, after 12 months of treatment despite no significant differences in weight, blood pressure, or lipid parameters [52]. These effects provided some reassurance about the CV safety and efficacy of DPP-4 inhibitors (Table 3).

**Table 3** DPP-4 inhibitors and left ventricular diastolic function

| Reference          | Sample size | Medication                  | Follow-up period | Main findings                                                                 |
|--------------------|-------------|-----------------------------|------------------|------------------------------------------------------------------------------|
| Nogueira et al. [50] | 35 DM patients | Sitagliptin | 24 weeks | Improvement in LV diastolic function was improved in 75% of DM patients       |
| Yamada et al. [51]     | 115 DM patients   | Sitagliptin | 24 months | Improvement of LV diastolic function (reduction in E/e′), but no change in LVEF |
| Leung et al. [52]       | 75 DM patients   | Sitagliptin Vildagliptin Saxagliptin | 12 months | Significant improvements in LV systolic, diastolic, and endothelial function |
| Kim et al. [53]       | 511,382 DM patients | Sitagliptin Linagliptin Vildagliptin Saxagliptin | 12 months | The risk for HF was reduced in all of the patients, in patients with baseline cardiovascular disease, and in patients without baseline cardiovascular disease compared with patients for sulfonylurea-treated patients. Sitagliptin and linagliptin showed statistically lower risk for hospitalization for HF than for sulfonylurea |
| McMurry et al. [54]   | 254 DM patients  | Vildagliptin | 52 weeks | No major effect on LVEF but increased LV volumes                               |
| Zhang et al. [17]    | 4790 DM patients (meta-analysis) | Sitagliptin Linagliptin Vildagliptin Teneligliptin Alogliptin Anagliptin | - | DPP-4 inhibitors are more strongly associated with a negative impact on LV end-diastolic volume |

*DPP-4* dipeptidyl peptidase 4 *DM* diabetes mellitus *LV* left ventricle *LVEF* left ventricular ejection fraction
Meta-analysis that compared parameters of LV systolic and diastolic function in DM patients treated with different antidiabetic drugs showed no difference in all parameters of LV diastolic function (e′, E/e′ and E/A) in patients treated with DPP-4 comparing with those who were treated with competitors (thiazolidinediones, SGLT-2 inhibitors and sulfonylurea) [17] (Table 3).

DPP-4 inhibitors and heart failure

Large investigation, which included more than 500,000 DM patients of whom half was treated with DDP-4 inhibitors, compared the effects of DPP-4 inhibitors with sulfonylurea and revealed no difference in the risk of HF between these two groups [53]. The authors even compared different DPP-4 inhibitors and found that sitagliptin and linagliptin were even associated with lower risk for hospitalization for HF than for sulfonylurea. Vildagliptin and saxagliptin also showed reduced risk for HF comparing with sulfonylurea, but the differences were not statistically significant [53].

A randomized placebo-control trial conducted in DM patients with HFrEF patients reported that vildagliptin did not change LVEF during 12-month therapy [54]. However, end-diastolic LV volume was significantly increased in patients treated with vildagliptin. The CARMELINA trial showed that linagliptin did not affect the incidence of hospitalization due to HF, the composite of cardiovascular death and hospitalization due to HF, or risk for recurrent HF events in comparison with placebo [55]. The meta-analysis that pooled data from five trials showed increased risk of admission for HF in patients treated with DPP-4 inhibitors versus control, but with borderline significance (HR 1.13; 95%CI 1.00–1.26) [56]. Nevertheless, it is difficult to make adjustment for all possible confounding factors in a meta-analysis, which can raise the question about its final results.

Other meta-analysis that included 4 trials, which investigated the effects of saxagliptin, alogliptin, sitagliptin, and linagliptin, separately analyzed the hospitalization rate due to HF in patients with and without prior history of HF, and found that DPP-4 inhibitors did not elevated risk of hospitalization due to HF in patients with previous HF, but in those DM patients without previous HF [57]. The same study reported borderline beneficial effect of GLP-1 receptor antagonists and significant positive effect of SGLT-2 inhibitors on the reduction of hospitalization in both groups, with and without history of HF. Conflicting results caused that authorities issued a warning about cautious prescription of DPP-4 inhibitors in patients with type 2 DM and a history of HF or kidney impairment [58]. The warning referred only on saxagliptin and alogliptin, but not other DPP-4 inhibitors. Nevertheless, one should underline that this is a very heterogeneous group of medications and some European Society for Heart Failure made clear discrepancy between saxagliptin that might increase risk of HF hospitalization and those DPP-4 inhibitors that have no impact on hospitalization (alogliptin, sitagliptin, vildagliptin, and linagliptin).

New studies that will be focused on this topic are warranted and particularly in patients with HFpEF in whom LVEF is not the main determinant. Ongoing TOPELEVEL study should determine the effect of DPP-4 inhibitor (teneligliptin) on LV diastolic function, using E/e′ as a main parameter, in type 2 DM patients and should answer the main question about the potential use of DPP-4 inhibitors in HFpEF [59]. Animal study reported that the inhibition of DPP-4 did not affect LV hypertrophy, but improved cardiac function and decreased myocardial and perivascular fibrosis [60]. These results indicate that DPP-4 inhibition decelerates the progression of HF by changing the quality and quantity of cardiac fibrosis, which might be the rational for usage of these medications in HFpEF patients.

Conclusion

New antidiabetic drugs have incremental influence on DM treatment, but their influence on CV outcome and particularly the effects in HF patients are still largely uninvestigated and possibly underestimated. The available data are very encouraging about the use of SGLT2 inhibitors in HFpEF patients, but their role in HFpEF individuals remain to be investigated. The effects of GLP-1R agonists and DPP-4 inhibitors in HF patients are significantly less investigated and results are controversial, particularly in the later group of medications. Therefore, currently ongoing trials should provide more information about effects of these medications in patients with HF and particularly in those with HFpEF. Preclinical studies reported positive effects of new antidiabetic drugs in HFpEF, which is of a great clinical importance due to limited therapeutic options that are currently available in this large group of HF patients.

Funding Open Access funding enabled and organized by Projekt DEAL.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Tadec M, Cuspidi C, Plein S, Belyavskiy E, Heinzel F, Galderisi M (2019) Sex and heart failure with preserved ejection fraction: from pathophysiology to clinical studies. J Clin Med 8(6):792

2. Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, Breathet K, Butler J, Davis LL, et al (2021) Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol 77(6):772–810

3. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al (2019) PARAGON-HF Investigators and Committees. Angiotensin-nephrilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 381(17):1609–1620

4. https://www.ajmc.com/view/entresto-wins-first-fda-nod-in-hard-to-treat-type-of-heart-failure

5. McMurray JJV, Solomon SD, Inzucchi SE, Köber L, Kosiborod MN, Martinez FA, et al (2019) DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 381(21):1995–2008

6. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al (2020) EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. Oct 8;383(15):1413–1424

7. Kramer CK, Ye C, Campbell S, Retnakaran R (2018) Comparison of new glucose-lowering drugs on risk of heart failure in type 2 diabetes: a network meta-analysis. JACC Heart Fail 6(10):823–830

8. Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bochicchi E, et al (2020) EMPEROR-Preserved Trial Committees and Investigators. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail 22(12):2383–2392

9. Wojcik C, Warden BA (2019) Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors. Curr Cardiol Rep 21(10):130

10. Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T et al (2018) 24-Hour blood pressure-lowering effect of an SGLT-2 Inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation 139(18):2089–2097

11. Teo YH, Teo YN, Syn NL, Kow CS, Yoong SY. Tan BYQ et al (2021) Effects of sodium/glucose cotransporter 2 (SGLT2) Inhibitors on cardiovascular and metabolic outcomes in patients without out diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc 10(5):e019463

12. Böhm M, Fitchett D, Østaf AD, Brueckmann M, Kaspers S, George JT, Zwiener I, Zinman B, Wanner C, Marx N, Mancia G, Anker SD, Mahfoud F (2020) Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. J Hypertens 38(9):1829–1840

13. Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH (2019) Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 9(1):13009

14. Ugusman A, Kumar J, Aminuddin A (2021) Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors. Pharmacol Ther Mar 1:107832 https://doi.org/10.1016/j.pharmthera.2021.107832 Epub ahead of print

15. Papadopoulou E, Loutradis C, Tsatzagou G, Kotsa K, Zografou I, Minopoulos I, Theodorakopoulou MP, Tsapas A, Karagiannis A, Sarafidis P (2021) Dapagliflozin decreases ambulatory central

blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. J Hypertens 39(4):749–758

16. Matthews VB, Elliot RH, Rudnicka A, Hricova J, Herat L, Schaich MP (2017) Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens 35(10):2059–2068

17. Zhang DP, Xu L, Wang LF, Wang JH, Jiang F (2020) Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis. Cardiovasc Diabetol 19(1):10

18. Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A et al (2016) Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 39:e212–e213

19. Cohen ND, Gutman, SJ, Briganti EM, Taylor AJ (2019) Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study. Intern Med J 49:1006–101

20. Rau M, Thiele K, Hartmann NK, Schuh A, Altiok E, Möllmann J, Keszei AP, Böhm M, Marx N, Lehrke M (2021) Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovasc Diabetol 20(1):6

21. Lan NSR, Yeo BB, Fegan PG, Green G, Rankin JM, Dwiwedi G (2021) Empagliflozin and left ventricular diastolic dysfunction following an acute coronary syndrome in patients with type 2 diabetes. Int J Cardiovasc Imaging 37(2):517–527

22. Eickhoff MK, Olsen FJ, Frimodt-Moller M, Diaz LJ, Faber J, Jensen MT, Rossing P, Persson F (2020) Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria—a double blind randomized placebo-controlled crossover trial. J Diabetes Complications 34(7):107590

23. Hwang IC, Cho GY, Yoon YE, Park JJ, Park JB, Lee SP, Kim HK, Kim YJ, Sohn DW (2020) Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Cardiovasc Diabetol 19(1):69

24. Shim CY, Seo J, Cho I, Lee CJ, Cho JJ, Lhavgasuren P, Kang SM, Ha JW, Han G, Jang Y, Hong GR (2021) Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus: the IDDDIA Trial. Circulation 143(5):510–512

25. Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horisuchi R, Utsunomiya K (2018) Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol 17(1):73

26. Otagaki M, Matsumura K, Kin H, Fuji K, Shibutani H, Matsumoto H, Takahashi H, Park H, Yamamoto Y, Sugita T, Shiojima I (2019) Effect of tofogliflozin on systolic and diastolic cardiac function in type 2 diabetic patients. Cardiovasc Drugs Ther 33(4):435–442

27. Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI (2018) Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol 17(1):132

28. Tanaka H, Soga F, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, Hirata KI (2020) Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Cardiovasc Diabetol 19(1):6

29. Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M (2019) Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc Diabetol 18(1):76
30. Scheffer M, Driessen-Waaijer A, Hamdani N, Landzaat JWD, Jonkman NH, Paulus WJ, van Heerebeek L (2020) Stratified treatment of heart failure with preserved ejection fraction: rationale and design of the STADIA-HFpEF trial. ESC Heart Fail 7(6):4478–4487

31. Heuvelman VD, Van Raalte DH, Smits MM (2020) Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res 116(5):916–930

32. Bizino MB, Jazrawi IM, Westenberg JJM, van Eyk HJ, Paiman EHM, Smit JWA, Lamb HJ (2019) Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol 18(1):55

33. Saponaro F, Songaigioni A, Rossi A, Montefusco L, Lombardo M, Adda G, Arosio M (2016) Improved diastolic function in type 2 diabetes after a six month liraglutide treatment. Diabetes Res Clin Pract 118:21–28

34. Hiramatsu T, Asano Y, Mabuchi M, Imai K, Iuchi D, Furuta S (2018) Liraglutide relieves cardiac dilated function than DPP-4 inhibitors. Eur J Clin Invest 48(10):e13007

35. Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, Fujiwara R, Takahashi H, Murata K (2020) Effects of oral anti-diabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Heart Fail Rev. Feb 21. https://doi.org/10.1007/s10741-020-09936-w. Epub ahead of print

36. Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, Georgiou D, Andreoudi I, Parisiss J, Triantafyllidi H, Lekakis J, Lioudromites E, Dimitriadis G, Ikonomidou I (2018) Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol 17(1):8

37. Kumarathurai P, Sadajeth A, Anholm C, Kristiansen OP, Haugard SB, Nielsen OW (2021) Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study. Cardiovasc Diabetol 20(1):12

38. Scalzo RL, Moreau KL, Özemek C, Herlache L, McMillin S, Gilligan S, Huebschmann AG, Bauer TA, Dorosz J, Reusch JE, Regensteiner JG (2017) Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. J Diabetes Complications 31(2):449–455

39. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500–508

40. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselfmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multi- centre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69–77

41. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L, Petrie MC, McMurray JLV (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome studies. Lancet Diabetes Endocrinol 7:776–785

42. Nguyen TD, Shingu Y, Amorim PA, Schenkli C, Schwarzer M, Doenst T (2018) GLP-1 improves diastolic function and survival in heart failure with preserved ejection fraction. J Cardiovasc Transl Res 11(3):259–267

43. Withaar C, Meems LGM, Markousis-Mavrogenis G, Boogerd CJ, Sillié HHW, Schouten EM, Dokter MM, Voors AA, Westenbrink BD, Lam CSP, de Boer RA (2020) The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of Heart Failure with Preserved Ejection Fraction. Cardiovasc Res. Sep 1 :cvaa256. https://doi.org/10.1093/cvr/cvaa256. Epub ahead of print

44. Scheen AJ (2018) Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122(10):1439–1459

45. Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35(6):992–1019

46. Scirica BM, Blatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–26

47. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–35

48. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Rosse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Strandl E, Stein PP, Suryawanshi A, Van der Werf F, Peterson ED, Holman RR (2015) TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373(3):232–42.

49. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N (2019) CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA Randomized Clinical Trial. Jama 322(12):1155–66

50. Nogueira KC, Furtado M, Fukui RT, Correia MR, Dos Santos RF, Andrade JL, Ross and Silva ME (2014) Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor—a pilot study. Diabetol Metab Syndr 6(1):103

51. Yamada H, Tanaka A, Kusunose K, Amano R, Matsushita M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K (2017) PROLOUGE Study Investigators. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOUGE study. Cardiovasc Diabetol 16(1):63

52. Leung M, Leung DY, Wong VW (2016) Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study. Diab Vasc Dis Res 13(3):236–243

53. Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, Park RW, Kim HJ (2017) Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study. Circ Heart Fail 10(9):e003957

54. McMurry JJ, Ponikowski P, Bolli GB, Lukashevich V, Kozlovskii P, Kothry W, Lewyse JD, Krum H (2018) VIVIDD Trial Committees and Investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 6(1):8–17

55. McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baastra D, Pfarr E, Schnaitt S, Meinicke T, George JT, von Eynatten M, Marx N (2019) CARMELINA Investigators. Linagliptin effects...
on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CAR-MELINA. Circulation 139(3):351–361

56. Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, Wong E, Busse JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X (2016) Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ 352:i610

57. Pan X, Xu S, Li J, Tong N (2020) The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 inhibitors on heart failure outcomes in diabetic patients with and without heart failure history: insights from CVOTs and drug mechanism. Front Endocrinol (Lausanne) 11:599355

58. US Food and Drug Administration. Diabetes medications containing saxagliptin and alogliptin: drug safety communication-risk of heart failure. (Apr 5, 2016). available at: https://www.fda.gov/media/96895/download

59. Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M (2019) TOLEVEL investigators and study coordinators. Effects of teneligliptin on the progressive left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus in open-label, marker-stratified randomized, parallel-group comparison, standard treatment-controlled multicenter trial (TOLEVEL Study): rationale and study design. Cardiovasc Drugs Ther 33(3):363–370

60. Hirose M, Takano H, Hasegawa H, Tadokoro H, Hashimoto N, Takemura G, Kobayashi Y (2017) The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure. J Pharmacol Sci 135(4):164–173

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.